Oculis Holding AG
NASDAQ:OCSBiotechnology
-$0.28 today
- Market cap
- $456.20M
- Beta
- 0.13
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.61
Volume 0.31M
Average 0.65M
OCS EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Oculis Holding AGNASDAQ: OCS
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -CHF 0.5, compared with -CHF 0.69 a year earlier. Trailing-twelve-month EPS (Basic) was -CHF 1.73.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 6 analysts of -CHF 1.4 (+22.7%) for the fiscal year ending Dec 2026, a step up from the +14.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CHF 0.5-19.0% QoQ
- Last fiscal yearDec 2025
- -CHF 1.81+14.6% YoY
- LTMMar 2026
- -CHF 1.73+27.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +27.5% | +21.3% | -6.3 pp |
| 1 year | +14.6% | +22.7% | +8.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
CHF · from the income statement
- Latest · FY2025
- (1.81) CHF
- Year-over-year change
- +14.6%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.81) | +14.6% |
| FY2024 | 2024-12-31 | (2.12) | +28.6% |
| FY2023 | 2023-12-31 | (2.97) | -151.7% |
| FY2022 | 2022-12-31 | (1.18) | -107.0% |
| FY2021 | 2021-12-31 | (0.57) | — |
EPS (Basic) vs competitors
How OCS compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +27.0% is the 2nd highest of 6, against a peer median of -45.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| FY2025 | -$0.12 USD | -19900.0% | — | |
| LTM Mar 2026 | -$0.39 USD | +35.7% | — | |
| LTM Mar 2026 | -$1.36 USD | -194.8% | — | |
| LTM Mar 2026 | -$1.46 USD | -27.0% | — | |
| LTM Mar 2026 | -CHF 1.73 CHF | +27.0% | — | |
| LTM Mar 2026 | -$3.5 USD | -45.2% | — | |
| Peer median (excluding OCS) | — | -45.2% | — | |
Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 686K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 52.08M | 0 |
| Gross Profit | 0 | 0 | 0 | (51.4M) | 0 |
| Gross Margin | — | — | — | -7492.3% | — |
| Research & Development | 9.57M | 22.22M | 29.25M | 52.08M | 54.52M |
| Selling, General & Admin | 4.1M | 6.74M | 14.72M | 21.81M | 24.63M |
| Operating Expenses | 13.23M | 32.38M | 80.71M | 21.81M | 79.15M |
| Depreciation & Amortization | 235K | 299K | 287K | 406K | 521.45K |
| EBITDA | (13.17M) | (31.9M) | (87.09M) | (85.53M) | (93.37M) |
| EBITDA Margin | — | — | — | -12468.1% | — |
| Operating Income | (13.23M) | (32.38M) | (80.71M) | (73.2M) | (79.15M) |
| Operating Margin | — | — | — | -10671.1% | — |
| Interest Income | 21K | 126K | 1.59M | 2.17M | 1.69M |
| Interest Expense | 5.12M | 6.44M | 1.46M | 639K | 795.55K |
| Other Income / Expenses | (5.29M) | (6.27M) | (7.98M) | (12.73M) | (15.54M) |
| Income Before Tax | (18.52M) | (38.64M) | (88.7M) | (85.94M) | (94.69M) |
| Pre-Tax Margin | — | — | — | -12527.3% | — |
| Income Tax Expense | 27K | 55K | 107K | (160K) | 177.64K |
| Net Income | (18.55M) | (38.7M) | (88.8M) | (85.78M) | (94.51M) |
| Net Margin | — | — | — | -12503.9% | — |
| EPS (Basic) | (0.57) | (1.18) | (2.97) | (2.12) | (1.81) |
| EPS (Diluted) | (0.57) | (1.18) | (2.97) | (2.12) | (1.81) |
| Weighted Avg Shares | 32.73M | 32.73M | 29.9M | 40.41M | 52.36M |
| Weighted Avg Shares (Diluted) | 32.73M | 32.73M | 29.9M | 40.41M | 52.36M |
Oculis Holding AG
NASDAQ:OCS
Intrinsic Alpha fair value
Locked
Current Price
$7.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.